H.C. Wainwright raised the firm’s price target on Armata Pharmaceuticals (ARMP) to $9 from $7 and keeps a Buy rating on the shares. The company this morning announced a “very big clinical win as well a defining moment for bacteriophage therapy,” the analyst tells investors in a research note. The firm says the Phase 1b/2a study, diSArm, has met all primary endpoints. The study and highlights, beyond the “strong” clinical responses, that from the petri dish to the patient, AP-SA02 shows the ability to home to site of infections, kill, amplify, and re-home to kill some more, before being cleared by the liver, contends H.C. Wainwright.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARMP:
- Armata Pharmaceuticals Reports Positive Phase 1b/2a Trial Results
- Armata reports data from Phase 1b/2a diSArm trial
- Armata Pharmaceuticals Inc (ARMP) Q1 Earnings Cheat Sheet
- Armata Pharmaceuticals receives $4.65M of funding from DoD
- Armata Pharmaceuticals: Promising Clinical Trials and Strong Financial Position Justify Buy Rating